2024-513276-17-00进行中（未招募）1 期
An Open-label, Multicenter, Phase 1b Study of OV-1001 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination with Background Therapy for the Treatment of Subjects with Acute Myeloid Leukemia
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 10
- 试验地点
- 3
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
OncoVerity Help Desk
Scientific
OncoVerity Inc.
研究点 (3)
Loading locations...
相似试验
招募中
1 期
Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-NNS309 in patients with pancreatic, lung, breast and colorectal cancers.2023-510356-23-00Novartis Pharma AG76
招募中
1 期
A Phase 1b, Open-Label, Single-Arm Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of ANX1502 in Participants with Primary Cold Agglutinin Disease2023-507017-10-00Annexon Inc.10
进行中（未招募）
1 期
An open-label, phase I multicenter, clinical trial of NECVAX-NEO1 in addition to anti-PD-1 or anti-PD-L1 monoclonal antibody checkpoint inhibitor monotherapy in patients with solid tumors2024-513716-95-00Nec Oncoimmunity AS6
招募中
1 期
A Phase 1b, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Clinical Activity of CND261 in Patients with Seropositive Rheumatoid Arthritis2025-523265-15-00Candid Therapeutics Inc.9
已完成
1 期
A Phase 1 Multicenter, Open Label, First-in-Human Dose Escalation Study of AFM28, a Bispecific ICE® that Targets CD123 and CD16A, in patients with CD123-Positive Relapsed/Refractory Acute Myeloid Leukemia2023-510021-16-00Affimed GmbH60